Why prostate cancer patients fail hormone deprivation therapy
December 31st, 2008 Posted in hormone therapyJohns Hopkins scientists identify receptor type that makes cancer cells resistant to therapy, more aggressive
The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to this therapy. The findings, reported in the Jan. 1 issue of Cancer Research, could lead to a way to track disease progression, as well as new targets to fight prostate cancer. [ more about ]